Isoprenoid-mediated inhibition of mevalonate synthesis: Potential application to cancer

Proceedings of the Society for Experimental Biology and Medicine

Volumn 221, Issue 4, 1999, Pages 294-311

  Elson, Charles E ^a   Peffley, Dennis M ^b   Hentosh, Patricia ^b   Mo, Huanbiao ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; ASCORBIC ACID; BETA CAROTENE; BETA IONONE; CHOLESTEROL; FARNESOL; GERANIOL; GROWTH HORMONE RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ISOPRENOID; LAMIN A; LAMIN B; LIMONENE; MESSENGER RNA; MEVINOLIN; PERILLYL ALCOHOL; RAS PROTEIN;

ANIMAL CELL; APOPTOSIS; CANCER INHIBITION; CANCER RISK; CHOLESTEROL INTAKE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME DEGRADATION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; MOUSE; NONHUMAN; PROTEIN PROCESSING; SHORT SURVEY; STEROIDOGENESIS; TUMOR GROWTH;

ANIMALIA;

EID: 0032868926     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1373.1999.d01-87.x     Document Type: Short Survey

References (315)

1. Committee on Diet, Nutrition, and Cancer. Diet, Nutrition, and Cancer. Washington, DC: National Academy Press, 1982.
2. U.S. Department of Agriculture, U.S. Department of Health and Human Services. Nutrition and Your Health: Dietary Guidelines for Americans. Washington, DC: U.S. Government Printing Office, Home and Garden Bulletin No. 232 (Fourth Edition), 1995.
3. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health. NCI monographs: Cancer Control Objectives for the Nation, 1985-2000. Washington, DC: U.S. Government Printing Office, NIH Publication No. 86-2880, 1986.
4. Butrum RR, Clifford CK, Lanza E. NCI dietary guidelines: Rationale. Am J Clin Nutr 48:S888-S895, 1988.
5. Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci USA 92:5258-5265, 1995.
6. Doll R. The lessons of life: Keynote address to the nutrition and cancer conference. Cancer Res 52:S2024-S2029, 1992.
7. Willett WC. Diet, nutrition, and avoidable cancer. Environ Health Perspect 103:S165-S170, 1995.
8. Willett WC. Can we prevent cancer by diet today? Proc Am Assn Cancer Res 37:644-645, 1996.
9. Austoker J. Diet and cancer. BMJ 308:1610-1614, 1994.
10. Hocman G. Prevention of cancer: Vegetables and plants. Comp Biochem Physiol B Biochem Mol Biol 93:201-212, 1989.
11. Verhoeven D, Assen N, Goldbohm RA, Dorant E, Vantveer P, Hermus RJJ, Vandenbrandt PA. Vitamins C and E, retinol, β-carotene and dietary fibre in relation to breast cancer risk: A prospective cohort study. Br J Cancer 75:149-155, 1997.
12. Albanes D, Heinonen OP, Taylor PR, Virtamo J, Edwards BK, Rautalahti M, Hartman AM, Palmgren J, Freedman LS, Haapakoski J, Barrett MJ, Pietinen P, Malila N, Tala E, Liippo K, Salomaa ER, Tangrea JA, Teppo L, Askin FB, Taskinen E, Erozan Y, Greenwald P, Huttunen JK. α-Tocopherol and β-carotene supplements and lung cancer incidence in the α-tocopherol, β-carotene cancer prevention study: Effects of baseline characteristics and study compliance. J Natl Cancer Inst 88:1560-1570, 1996.
13. Bruemmer B, White E, Vaughan TL, Cheney CL. Nutrient intake in relation to bladder cancer among middle-aged men and women. Am J Epidemiol 144:485-495, 1996.
14. Potischman N, Brinton LA. Nutrition and cervical neoplasia. Cancer Causes Control 7:113-126, 1996.
15. Steinmetz KA, Folsom AR. Reduced risk of colon cancer with high intake of vitamin E: The Iowa women's health study. Cancer Res 53:4230-4237, 1993.
16. Butterworth CE Jr., Hatch KD, Macaluso M, Cole P, Sauberlich HE, Soong SJ, Borst M, Baker VV. Folate deficiency and cervical dysplasia. JAMA 267:528-533, 1992.
17. Giovannucci E, Stampfer MJ, Colditz GA, Rimm EB, Trichopoulos D, Rosner BA, Sperzer FE, Willett WC. Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst 85:875-884, 1993.
18. Trock B, Lanza E, Greenwald P. Dietary fiber, vegetables, and colon cancer: Critical review and meta-analyses of the epidemiologic data. J Natl Cancer Inst 82:650-661, 1990.
19. Wattenberg LW. Inhibition of neoplasia by minor dietary constituents. Cancer Res 43:S2448-S2453, 1983.
20. Wattenberg LW. Inhibition of carcinogenesis by minor anutrient constituents of the diet. Proc Nutr Soc 49:173-183, 1990.
21. Wattenberg LW. Inhibition of carcinogenesis by minor dietary constituents. Cancer Res 52:S2085-S2091, 1992.
22. Wattenberg LW. Chemoprevention of cancer. Prev Med 25:44-45, 1996.
23. Elson CE, Maltzman TH, Boston JL, Tanner MA, Gould MN. Anticarcinogenic activity of d-limonene during the initiation and promotion/progression stages of DMBA-induced rat mammary carcinogenesis. Carcinogenesis 9:331-332, 1988.
24. Sacchettini JC, Poulter CD. Creating isoprenoid diversity. Science 277:1788-1789, 1997.
25. Bach TJ. Some new aspects of isoprenoid biosynthesis in plants: A review. Lipids 30:191-202, 1995.
26. Wendt KU, Schulz GE. Isoprenoid biosynthesis: Manifold chemistry catalyzed by similar enzymes. Structure (London) 6:127-133, 1998.
27. Barron D, Ibrahim RA. Isoprenylated flavonoids: A survey. Phytochem 43:921-982, 1996.
28. Qureshi AA, Burger WC, Peterson DA, Elson CE. The structure of an inhibitor of cholesterol biosynthesis isolated from barley. J Biol Chem 261:10544-10550, 1986.
29. Parker RA, Pearce BC, Clark RW, Gordan DA, Wright JJK. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem 268:11230-11238, 1993.
30. Bennis F, Favre G, Le Gaillard F, Soula G. Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549. Int J Cancer 55:640-645, 1993.
31. Elegbede JA, Elson CE, Qureshi AA, Dennis WH, Yatvin MB. Increasing the thermosensitivity of a mammary tumor (CA755) through dietary modification. Eur J Cancer Clin Oncol 22:607-615, 1986.
32. Clegg RJ, Middleton B, Bell GD, White DA. The mechanism of cyclic monoterpene inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase in vivo in the rat. J Biol Chem 257:2294-2299, 1982.
33. Haq PU, Din ZZ, Shrago E, Elson CE, Qureshi AA. Inhibition of hepatic cholesterogenesis by d-limonene and abscisic acid in chickens. Fed Proc 43:1866A, 1984.
34. Elson CE, Yu SG. The chemoprevention of cancer by mevalonate-derived constituents of fruits and vegetables. J Nutr 124:607-614, 1994.
35. Elson CE. Suppression of mevalonate pathway activities by dietary isoprenoids: Protective roles in cancer and cardiovascular disease. J Nutr 125:S1666-S1672, 1995.
36. Elson CE. Novel lipids and cancer: Isoprenoids and other phytochemicals. In: Heber D, Kritchevsky D, Eds. Dietary Fats, Lipids, Hormones, and Tumorigenesis. New York: Plenum Publishing Corporation, pp 71-86, 1996.
37. Mo H, Peffley DM, Elson CE. Targeting the action of isoprenoids and related phytochemicals to tumors. In: Heber D, Blackburn GL, Go VLW, Eds. Nutritional Oncology. San Diego, CA: Academic Press, pp 379-391, 1998.
38. Elegbede JA, Elson CE, Tanner MA, Qureshi AA, Gould MN. Regression of rat primary mammary tumors following dietary dlimonene. J Natl Cancer Inst 76:323-325, 1986.
39. Haag JD, Gould MN. Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene. Cancer Chemother Pharmacol 34:477-483, 1994.
40. Mo H, Elson CE. Apoptosis and cell-cycle arrest in human and murine tumor cells are initiated by isoprenoids. J Nutr 129:804-813, 1999.
41. Yaguchi M, Miyazawa K, Katagiri T, Nishimaki J, Kizaki M, Tohyama K, Toyama K. Vitamin K2 and its derivatives induce apoptosis in leukemia cells and enhance the effect of all-trans-retinoic acid. Leukemia 11:779-787, 1997.
42. Adany I, Yazlovitskaya EM, Haug JS, Voziyan PA, Melnykovych G. Differences in sensitivity to farnesol toxicity between neoplastically-and non-neoplastically-derived cells in culture. Cancer Lett 79:175-179, 1994.
43. Melnykovysh G, Haug JS, Goldner CM. Growth inhibition of leukemia cell line CEM-C1 by farnesol: Effects of phosphatidylcholine and diacylglycerol. Biochem Biophys Res Commun 186:543-548, 1992.
44. Kawata S, Nagase T, Yamasaki E, Ishiguro H, Matsuzawa Y. Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2). Br J Cancer 69:1015-1020, 1994.
45. Miquel K, Pradines A, Favre G. Farnesol and geranylgeraniol induce actin cytoskeleton disorganization and apoptosis in A549 lung adenocarcinoma cells. Biochem Biophys Res Commun 225:869-876, 1996.
46. Levy J, Bosin E, Feldman B, Giat Y, Miinster A, Danilenko M, Sharoni Y. Lycopene is a more potent inhibitor of human cancer cell proliferation than either α-carotene or β-carotene. Nutr Cancer 24:257-266, 1995.
47. Burke YD, Stark MJ, Roach SL, Sen SE, Crowell PL. Inhibition of pancreatic cancer growth by the dietary isoprenoids farnesol and geraniol. Lipids 32:151-156, 1997.
48. Yazlovitskaya EM, Melnykovych G. Selective farnesol toxicity and translocation of protein kinase C in neoplastic HeLa-S3K and non-neoplastic CF-3 cells. Cancer Lett 88:179-183, 1995.
49. Stayrook KR, McKinzie JH, Burke YD, Burke YA, Crowell PL. Induction of the apoptosis-promoting protein Bak by perillyl alcohol in pancreatic ductal adenocarcinoma relative to untransformed ductal epithelial cells. Carcinogenesis 18:1655-1658, 1997.
50. Yu SG, Hildebrandt LA, Elson CE. Geraniol, an inhibitor of mevalonate biosynthesis, suppresses the growth of hepatomas and melanomas transplanted to rats and mice. J Nutr 125:2763-2767, 1995.
51. Shoff SM, Grummer M, Yatvin MB, Elson CE. Concentration-dependent increase in murine P388 and B16 population doubling time by the acyclic monoterpene geraniol. Cancer Res 51:37-42, 1991.
52. Broitman SA, Wilkinson J IV, Cerda S, Branch SK. Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic metastases in vivo. In: American Institute for Cancer Research, Ed. Dietary Phytochemicals in Cancer Prevention and Treatment. New York: Plenum Press, pp 111-130, 1996.
53. He L, Mo H, Hadisusilo S, Qureshi AA, Elson CE. Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. J Nutr 127:668-674, 1997.
54. Yu SG, Anderson PJ, Elson CE. The efficacy of β-ionone in the chemoprevention of rat mammary carcinogenesis. J Agric Food Chem 43:2144-2147, 1995.
55. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature (London) 343:425-430, 1990.
56. Brown MS, Goldstein JL. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 21:505-517, 1980.
57. Jackson SM, Ericsson J, Edwards PA. Signaling molecules derived from the cholesterol biosynthetic pathway. Subcellular Biochem 28:1-21, 1997.
58. Faust JR, Goldstein JL, Brown MS. Synthesis of ubiquinone and cholesterol in human fibroblasts: Regulation of a branched pathway. Arch Biochem Biophys 192:86-89, 1979.
59. Peffley DM, Gayen AK. Inhibition of squalene synthase but not squalene cyclase prevents mevalonate-mediated suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis at a post-transcriptional level. Arch Biochem Biophy 337:251-260, 1997.
60. Peffley D, Sinensky M. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis by a nonsterol mevalonate-derived product in Mev-1 cells. J Biol Chem 260:9949-9952, 1985.
61. Peffley DM. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase synthesis in Syrian hamster C100 cells by mevinolin, 25-hydroxycholesterol, and mevalonate: The role of post-transcriptional control. Somat Cell Mol Genet 18:19-32, 1992.
62. Nakanishi M, Goldstein JL, Brown MS. Multivalent control of 3-hydroxy-3-methylglutaryl coenzyme A reductase: Mevalonate-derived product inhibits translation of mRNA and accelerates degradation of enzyme. J Biol Chem 263:8929-8937, 1988.
63. Peffley D, Miyake J, Leonard S, vonGunten C, Sinensky M. Further characterization of a somatic cell mutant defective in regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Somat Cell Mol Genet 14:527-539, 1988.
64. Choi JW, Lundquist EN, Peffley DM. Inhibition of protein synthesis in baby hamster kidney cells blocks oxysterol-mediated suppression of 3-hydroxy-3-methylglutaryl-CoA reductase mRNA at a post-transcriptional level. Biochem J 296:859-866, 1993.
65. Clarke CF, Fogelman AM, Edwards PA. Diurnal rhythm of rat liver mRNAs encoding 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Biol Chem 259:10439-10447, 1984.
66. Osborne TF, Goldstein JL, Brown MS. 5′-End of HMG-CoA reductase gene contains sequences responsible for cholesterol-mediated inhibition of transcription. Cell 42:203-212, 1985.
67. Osborne TF, Gil G, Goldstein JL, Brown MS. Operator constitutive mutation of 3-hydroxy-3-methylglutaryl coenzyme A reductase promoter abolishes protein binding to sterol regulatory element. J Biol Chem 263:3380-3387, 1988.
68. Gil G, Smith JR, Goldstein JL, Slaughter CA, Orth K, Brown MS, Osborne TF. Multiple genes encode nuclear factor 1-like proteins that bind to the promoter for 3-hydroxy-3-methylglutaryl coenzyme A reductase. Proc Natl Acad Sci USA 85:8963-8967, 1988.
69. Reynolds GA, Basu SK, Osborne TF, Chin DJ, Gil G, Brown MS, Goldstein JL, Luskey KL. HMG-CoA reductase: A negatively regulated gene with unusual promoter and 5′ untranslated regions. Cell 38:275-286, 1984.
70. Skalnik DG, Brown DA, Brown PC, Friedman RL, Hardeman EC, Schimke RF, Simoni RD. Mechanisms of 3-hydroxy-3-methylglutaryl coenzyme A reductase overaccumulation in three compactin-resistant cell lines. J Biol Chem 260:1991-1994, 1985.
71. Field JF, Shreves T, Fujiwara D, Murthy S, Albright E, Mathur SN. Regulation of gene expression and synthesis and degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase by micellar cholesterol in CaCo-2 cells. J Lipid Res 32:1811-1821, 1991.
72. Tanaka RD, Edwards PA, Lau SF, Fogelman AM. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A activity in avian rnyeloblasts. J Biol Chem 258:13331-13339, 1980.
73. Trzaskos JM, Magolda RL, Favata MG, Fischer RT, Johnson PR, Chen HW, Ko SS, Leonard DA, Gaylor JL. Modulation of 3-hydroxy-3-methylglutaryl-CoA reductase by 15α-fluorolanost-7-en-3β-ol: A mechanism-based inhibitor of cholesterol biosynthesis. J Biol Chem 268:22591-22599, 1993.
74. Tam SP, Brissette L, Ramharack R, Deeley RG. Differences between the regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low-density lipoprotein receptor in human hepatoma cells and fibroblasts reside primarily at the translational and post-translational levels. J Biol Chem 266:16764-16773, 1991.
75. Edwards PA, Lan SF, Tanaka RD, Fogelman AM. Mevalonolactone inhibits the rate of synthesis and enhances the rate of degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in rat hepatocytes. J Biol Chem 258:7272-7275, 1983.
76. Hardeman E, Endo A, Simoni R. Effects of compactin on the levels of 3-hydroxy-3-methylglutaryl coenzyme A reductase in compactin-resistant C100 and wild-type cells. Arch Biochem Biophys 232:549-561, 1984.
77. Parker RA, Miller SJ, Gibson DM. Phosphorylation of native 97-kDa 3-hydroxy-3-methylglutaryl coenzyme A reductase from rat liver. J Biol Chem 264:4877-4887, 1989.
78. Correll CC, Edwards PA. Mevalonic acid-dependent degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in vivo and in vitro. J Biol Chem 269:633-638, 1994.
79. Gil G, Faust JR, Chin DJ, Goldstein JL, Brown MS. Membrane-bound domain of HMG-CoA reductase is required for sterol-enhanced degradation of the enzyme. Cell 41:249-258, 1985.
80. Sinensky S, Logel J. Inhibition of degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase by mevinolin. J Biol Chem 258:8547-8549, 1983.
81. Meigs TE, Simoni RD. Farnesol as a regulator of HMG-CoA reductase degradation: Characterization and role of farnesyl pyrophosphatase. Arch Biochem Biophys 345:1-9, 1997.
82. Correll CC, Ng L, Edwards PA. Identification of farnesol as the nonsterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem 269:17390-17393, 1994.
83. Meigs TE, Roseman DS, Simoni RD. Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo. J Biol Chem 271:7916-7922, 1996.
84. Osborne TF, Bennett M, Rhee K. Red25, a protein that binds specifically to the sterol regulatory region in the promoter for 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Biol Chem 267:18973-18982, 1992.
85. Hentze MW, Caughman SW, Rouault TA, Barriocanal JG, Dancis A, Harford JB, Klausner RD. Identification of the iron-responsive element for the translational regulation of human ferritin mRNA. Science 238:1570-1573, 1987.
86. Vallet SM, Sanchez HB, Rosenfeld JM, Osborne TF. A direct role for sterol regulatory element binding protein in activation of 3-hydroxy-3-methylglutaryl coenzyme A reductase gene. J Biol Chem 271:12247-12253, 1996.
87. Christophe J, Popjak G. Studies on the biosynthesis of cholesterol: The origin of prenoic acids from allyl pyrophosphates in liver enzyme systems. J Lipid Res 2:244-257, 1961.
88. Bansal VS, Vaidya S. Characterization of two distinct allyl pyrophosphatase activities from rat liver microsomes. Arch Biochem Biophys 315:393-399, 1994.
89. Westfall D, Aboushadi N, Shackelford JE, Krisans SK. Metabolism of farnesol: Phosphorylation of farnesol by rat liver microsomal and peroxisomal fractions. Biochem Biophys Res Commun 230:562-568, 1997.
90. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, Noonan DJ, Burka LT, McMorris T, Lamph WW, Evans RM, Weinberger C. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81:687-693, 1995.
91. Meier CA. Regulation of gene expression by nuclear hormone receptors. J Recept Signal Transduct Res 17:319-335, 1997.
92. Austin CA, Shephard EA, Pike SF, Rabin BR, Phillips JR. The effect of terpenoid compounds on cytochrome P-450 levels in rat liver. Biochem Pharmacol 37:2223-2229, 1988.
93. Bostedor RG, Karkas JD, Arison BH, Bansal VS, Vaidya S, Germershausen JI, Kurtz MM, Bergstrom JD. Farnesol-derived dicarboxylic acids in the urine of animals treated with zaragozic acid A or with farnesol. J Biol Chem 272:9197-9203, 1997.
94. Gonzalez-Pacanowska D, Arison B, Havel CM, Watson JA. Isopentenoid synthesis in isolated embryonic Drosophila cells. II. Farnesol catabolism and ω-oxidation. J Biol Chem 263:1301-1306, 1988.
95. Julia P, Pares X, Jornvall H. Rat liver alcohol dehydrogenase of class III. Primary structure, functional consequences and relationships to other alcohol dehydrogenases. Eur J Biochem 172:73-83, 1988.
96. Keung WM. Human liver alcohol dehydrogenases catalyze the oxidation of the intermediary alcohols of the shunt pathway of mevalonate metabolism. Biochem Biophys Res Commun 174:701-707, 1991.
97. Rout UK, Elkington JSH, Holmes RS. Developmental changes in aldehyde dehydrogenases from mouse tissues. Mech Ageing Dev 40:103-113, 1987.
98. Cohen LH, Griffioen M. Regulation of 3-hydroxy-3-methylglutaryl CoA reductase mRNA contents in human hepatoma cell line HepG2 by distinct classes of mevalonate-derived metabolites. Biochem J 255:61-67, 1988.
99. Brown EJ, Schreiber SL. A signaling pathway to translational control. Cell 86:517-520, 1996.
100. Seydoux G. Mechanisms of translational control in early development. Curr Opin Genet Dev 6:555-561, 1996.
101. Peffley DM, Gayen AK. Mevalonate regulates polysome distribution and blocks translation-dependent suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA: Relationship to translational control. Somat Cell Mol Genet 21:198-204, 1995.
102. Giron MD, Havel CM, Watson JA. Mevalonate-mediated suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase function in α-toxin perforated cells. Proc Natl Acad Sci USA 91:6398-6402, 1994.
103. Fritz TN, Buechler RD, Peffley DM. Translational efficiency of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is regulated by 5′ untranslated (UTR) mRNA secondary structure. Circulation 98:379A, 1998.
104. Choi JW, Peffley DM. 3′-Untranslated sequences mediate post-transcriptional regulation of 3-hydroxy-3-methylglutaryl-CoA reductase mRNA by 25-hydroxycholesterol. Biochem J 307:233-238, 1995.
105. Potter VR. The biochemical approach to the cancer problem. Fed Proc 17:691-697, 1958.
106. Siperstein MD, Fagan VM. Deletion of the cholesterol-negative feedback system in liver tumors. Cancer Res 24:1108-1115, 1964.
107. Chen HW, Kandutsch AA, Heineiger HJ. The role of cholesterol in malignancy. Prog Exp Tumor Res 22:275-316, 1978.
108. George R, Goldfarb S. Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in Morris hepatoma 7800 after intravenous injection of mevalonic acid. Cancer Res 40:4717-4721, 1980.
109. Gregg RG, Sabine JR, Wilce PA. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in rat liver and Morris hepatomas 5123C, 9618A, and 5123tc. Biochem J 204:457-462, 1982.
110. Yachnin S, Toub DB, Mannickarottu V. Divergence in cholesterol biosynthetic rates and 3-hydroxy-3-methylglutaryl-CoA reductase activity as a consequence of granulocyte versus monocyte-macrophage differentiation in HL-60 cells. Proc Natl Acad Sci USA 81:894-897, 1984.
111. Bruscalalupi G, Leoni S, Mangiantini MT, Minieri M, Spagnuolo S, Trentlanc A. True uncoupling between cholesterol synthesis and 3-hydroxy-3-methylglutaryl coenzyme A reductase in an early stage of liver generation. Cell Mol Biol 31:365-368, 1985.
112. Engstrom W, Schofield PN. Expression of the 3-hydroxy-3-methylglutaryl coenzyme A-reductase and LDI-receptor genes in human embryonic tumors and in normal fetal tissues. Anticancer Res 7:337-342, 1987.
113. Erickson SK, Cooper AD, Barnard GF, Havel CM, Watson JA, Feingold KR, Moser AH, Hughes-Fulford M, Siperstein MD. Regulation of cholesterol metabolism in a slow-growing hepatoma in vivo. Biochim Biophys Acta 960:131-138, 1988.
114. Azrolan NI, Coleman PS. A discoordinant increase in the cellular amount of 3-hydroxy-3-methylglutaryl-CoA reductase results in the loss of rate-limiting control over cholesterogenesis in a tumor cell-free system. Biochem J 258:421-425, 1989.
115. Bennis F, Favre G, Le Gaillard F, Soula G. Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549. Int J Cancer 55:640-645, 1993.
116. Coni P, Pang J, Pichiri-Coni G, Hsu S, Rao PM, Rakalakshmi S, Sarma DSR. Hypomethylation of β-hydroxy-β-methylglutaryl coenzyme A reductase gene and its expression during hepatocarcinogenesis in the rat. Carcinogenesis 13:497-499, 1992.
117. Rossiello MR, Rao P, Rajalakshmi S, Sarma DAR. Similar patterns of hypomethylation in the β-hydroxy-β-methylglutaryl coenzyme. A reductase gene in hepatic nodules induced by different carcinogens. Mol Carcinog 10:237-245, 1994.
118. Woitek S, Unkles SE, Kinghorn JR, Tudzynski B. 3-Hydroxy-3-methylglutaryl-CoA reductase gene of Gibberella fujikuroi: Isolation and characterization. Curr Genet 31:38-47, 1997.
119. Hampton RY, Rine J. Regulated degradation of HMG-CoA reductase, an integral membrane protein of the endoplasmic reticulum, in yeast. J Cell Biol 125:299-312, 1994.
120. Hampton RY, Bhakta H. Ubiquitin-mediated regulation of 3-hydroxy-3-methylglutaryl-CoA reductase. Proc Natl Acad Sci USA 94:12944-12948, 1997.
121. Lum PY, Wright R. Degradation of HMG-CoA reductase-induced membranes in the fission yeast, Schizosaccharomyces pombe. J Cell Biol 131:81-94, 1995.
122. Lum PY, Edwards S, Wright R. Molecular, functional, and evolutionary characterization of the gene encoding HMG-CoA reductase in the fission yeast, Schizosaccharomyces pombe. Yeast 12:1107-1124, 1996.
123. Dimster-Denk D, Thorsness MK, Rine J. Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in Saccharomyces cervisiae. Mol Biol Cell 5:655-665, 1994.
124. Parrish ML, Sengstag C, Rine JD, Wright RL. Identification of the sequences in HMG-CoA reductase required for karmellae assembly. Mol Biol Cell 6:1535-1547, 1995.
125. Koning AJ, Roberts CJ, Wright RL. Different subcellular localization of Saccharomyces cerevisiae HMG-CoA reductase isozymes at elevated levels corresponds to distinct endoplasmic reticulum membrane proliferations. Mol Biol Cell 7:769-789, 1996.
126. Coppens I, Courtoy PJ. The mevalonate pathway in parasitic protozoa and helminths. Exp Parasitol 82:76-85, 1996.
127. Rajkovic A, Simonsen JN, Davis RE, Rottman FM. Molecular cloning and sequence analysis of 3-hydroxy-3-methylglutaryl-coenzyme A reductase from the human parasite Schistoma mansoni. Proc Natl Acad Sci USA 86:8217-8221, 1989.
128. Vandewaa EA, Mills G, Chen GZ, Foster LA, Bennett JL. Physiological role of HMG-CoA reductase in regulating egg production by Schistoma mansoni. Am J Physiol 257 (Regulatory Integrative Comp Physiol 26):R618-R625, 1989.
129. Casals N, Buesa C, Piulachs MD, Cabano J, Marrero PF, Belles X, Hegardt FG. Coordinated expression and activity of 3-hydroxy-3-methylglutaryl coenzyme A synthase and reductase in the fat body of Blattella germanica (L.) during vitellogenesis. Insect Biochem Mol Biol 26:837-843, 1996.
130. Gertler FB, Chiu CY, Richter ML, Chin DJ. Developmental and metabolic regulation of the Drosophila melannogaster 3-hydroxy-3-methylglutaryl coenzyme A reductase. Mol Cell Biol 8:2713-2721, 1988.
131. Liscum L, Cummings RD, Anderson RGW, Demartino GN, Goldstein JL, Brown MS. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (EC 1.1.1.34): A transmembrane glycoprotein of the endoplasmic reticulum with N-linked "high-mannose" oligosaccharides. Proc Natl Acad Sci USA 80:7165-7169, 1983.
132. Engfelt WH, Shackelford JE, Aboushadi N, Jessani N, Masuda K, Paton VG, Keller GA, Krisans SK. Characterization of UT2 cells: The induction of peroxisomal 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem 272:24579-24587, 1997.
133. Field FJ, Erickson SK, Shrewsbury MA, Cooper AD. 3-Hydroxy-3-methylglutaryl coenzyme A reductase (EC 1.1.1.34) from rat intestine: Subcellular localization and in vitro regulation. J Lipid Res 23:105-113, 1982.
134. Schmidt RA, Schneider CJ, Glomset JA. Evidence for post-translational incorporation of a product of mevalonic acid into Swiss 3T3 cell proteins. J Biol Chem 259:10175-10180, 1984.
135. Wolda SL, Glomset JA. Evidence for the modification of lamin B by a product of mevalonic acid. J Biol Chem 263:5997-6000, 1988.
136. Beck LA, Hosick TJ, Sinensky M. Incorporation of a product of mevalonic acid metabolism into proteins of Chinese ovary cell nuclei. J Cell Biol 107:1307-1316, 1988.
137. Farnsworth CC, Wolda SL, Gelb MH, Glomset JA. Human lamin B contains a farnesylated cysteine residue. J Biol Chem 264:20422-20429, 1989.
138. Hancock JF, Magee AI, Childs JE, Marshall CJ. All ras proteins are isoprenylated but only some are palmitoylated. Cell 577:1167-1177, 1989.
139. Shafer WR, Kim R, Sterne R, Thorner J, Kim SH, Rine J. Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science 245:379-385, 1989.
140. Casey PJ, Solski PA, Der CJ, Buss JE. P21 ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 86:8323-8327, 1989.
141. Maltese WA, Erdman RA. Characterization of isoprenoid involved in the post-translational modification of mammalian cell proteins. J Biol Chem 264:18168-18172, 1989.
142. Maltese WA. Post-translational modification of proteins by isoprenoids in mammalian cells. FASEB J 4:3319-3328, 1990.
143. Sinensky M, Lutz RJ. The prenylation of proteins. Bioessays 14:25-31, 1992.
144. Marshall CJ. Protein prenylation: A mediator of protein-protein interactions. Science 259:1865-1866, 1993.
145. Zhang FL, Casey PJ. Protein prenylation: Molecular mechanisms and functional consequences. Annu Rev Biochem 65:241-269, 1996.
146. Gelb MH. Protein prenylation, et cetera: Signal transduction in two dimensions. Science 275:1750-1751, 1997.
147. Hutchinson CJ, Bridger JM, Cox CS, Kill IR. Weaving a pattern from disparate threads: Lamin function in nuclear assembly and DNA replication. J Cell Sci 107:3259-3269, 1994.
148. Hennekes H, Nigg EA. The role of isoprenylation in membrane attachment of nuclear lamins: A single point mutation prevents proteolytic cleavage of the lamin A precursor and confers membrane binding properties. J Cell Sci 107:1019-1029, 1994.
149. Moir RD, Spann TP, Goldman RD. The dynamic properties and possible functions of nuclear lamins. Int Rev Cytol 162:141-182, 1995.
150. Bruscalupi G, Di Croce L, Lamartina S, Zaccaria ML, Luzatto AC, Trentalance A. Nuclear lamina reassembly in the first cell cycle of rat liver regeneration. J Cell Physiol 171:135-142, 1997.
151. Gibbs JB, Oliff A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 37:143-166, 1997.
152. Kelloff GJ, Lubet RA, Fay JR, Steele VE, Boone CW, Crowell JA, Sigman CC. Farnesyl protein transferase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 6:267-282, 1997.
153. Lobell RB, Kohl NE. Pre-clinical development of farnesyltransferase inhibitors. Cancer Metastasis Rev 17:203-210, 1998.
154. Crowell PL, Chang RR, Ren Z, Elson CE, Gould MN. Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen d-limonene and its metabolites. J Biol Chem 266:17679-17685, 1991.
155. Crowell PL, Lin S, Vedejs E, Gould MN. Identification of circulating metabolites of the antitumor agent d-limonene capable of inhibiting protein isoprenylation and cell growth. Cancer Chemother Pharmacol 31:205-212, 1992.
156. Crowell PL, Ren Z, Lin S, Vedejs E, Gould MN. Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation. Biochem Pharmacol 47:1405-1415, 1994.
157. Crowell PL, Elson CE, Bailey HH, Elegbede A, Haag JD, Gould MN. Human metabolism of the experimental cancer therapeutic agent d-limonene. Cancer Chemother Pharmacol 35:31-37, 1994.
158. Ren Z, Elson CE, Gould MN. Inhibition of type I and type II geranylgeranyl-protein transferases by the monoterpene perillyl alcohol in NIH3T3 cells. Biochem Pharmacol 54:113-120, 1997.
159. Hohl RJ. Monoterpenes as regulators of malignant cell proliferation. In: American Institute for Cancer Research, Eds. Dietary Phytochemicals in Cancer Prevention and Treatment. New York: Plenum Press, pp 137-146, 1996.
160. National Cancer Institute (NCI). Cancer Trials [On-line]. Available: http://cancertrials.nci.nih.gov, 1999.
161. Nagourney RA. Oral limonene: Combined prenylation inhibitor therapy of cancer. J Med Foods 1:83-88, 1998.
162. Brown MS, Faust JR, Goldstein JL, Kaneko I, Endo A. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem 253:1121-1128, 1978.
163. Sinenski M, Logel J. Defective macromolecule biosynthesis and cell cycle progression in a mammalian cell starved for mevalonate. Proc Natl Acad Sci USA 82:3257-3261, 1985.
164. Langan TJ, Volpe JJ. Cell cycle-specific requirement for mevalonate but not for cholesterol, for DNA synthesis in glial primary cultures. J Neurochem 49:513-521, 1987.
165. Doyle JW, Kandutsche AA. Requirement for mevalonate in cycling cells: Quantitative and temporal aspects. J Cell Physiol 137:133-140, 1988.
166. Fairbanks KD, Barbu VD, Witte LD, Weinstein IB, Goodman DS. Effects of mevinolin and mevalonate on cell growth in several transformed cell lines. J Cell Physiol 127:216-222, 1986.
167. Maltese WA, Sheridan KM. Isoprenylated proteins in cultured cells: Subcellular distribution and changes related to altered morphology and growth arrest induced by mevalonate deprivation. J Cell Physiol 133:471-481, 1987.
168. Panini SR, Schnitzer-Polokoff R, Spencer TA, Sinenski M. Sterol-independent regulation of 3-hydroxy-3-methylglutaryl-CoA reductase by mevalonate in Chinese hamster ovary cells. J Biol Chem 264:11044-11052, 1989.
169. Anonymous. Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV. Arch Intern Med 153:1079-1087, 1993.
170. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2:483-491, 1996.
171. Piscitelli SC, Thibault A, Figg WD, Tompkins A, Headlee D, Lieberman R, Samid D, Myers CE. Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. J Clin Pharmacol 35:368-373, 1995.
172. Prasanna P, Thibault A, Liu L, Samid D. Lipid metabolism as a target for brain cancer therapy: Synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J Neurochem 66:710-716, 1996.
173. Carducci MA, Bowling MK, Eisenberger MA, Sinibaldi V, Simons JW, Chen TL, Noe D, Grochow LB, Donehower RC. Phenylbutyrate (PB) for refractory solid tumors: A phase I clinical and pharmacologie evaluation. Proc Am Soc Clin Oncol 15:A1542, 1996.
174. Thibault A, Figg WD, Samid D. A phase I study of the differentiating agent phenylbutyrate in patients with cancer. Proc Am Soc Clin Oncol 15:A1539, 1996.
175. Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ, Myers CE. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer 75:2932-2938, 1995.
176. Samid D, Hudgins WR, Shack S, Liu L, Prasanna P, Myers C. Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. Adv Exp Med Biol 400A:501-505, 1997.
177. Cuthbert JA, Lipsky PE. Regulation of proliferation and ras localization in transformed cells by products of mevalonate metabolism. Cancer Res 57:3498-3505, 1997.
178. Raiteri M, Amaboldi L, McGeady P, Gelb MH, Verri D, Tagliabue C, Quarato P, Ferraboschi P, Santaniello E, Paoletti R, Fumagalli R, Corsini A. Pharmacological control of the mevalonate pathway: Effect on arterial smooth muscle cell proliferation. J Pharmacol Exp Ther 281:1144-1153, 1997.
179. Danesi R, Nardini D, Basolo F, Del Tacca M, Samid D, Myers CE. Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. Mol Pharmacol 49:972-979, 1996.
180. DeClue JE, Vass WC, Papageorge AG, Lowy DR, Willumsen BM. Inhibition of cell growth by lovastatin is independent of ras function. Cancer Res 51:712-717, 1991.
181. Ruch RJ, Sigler K. Growth inhibition of rat liver epithelial tumor cells does not involve ras plasma membrane association. Carcinogenesis 15:787-789, 1994.
182. Hawk MA, Cesen KT, Siglin JC, Stoner GD, Ruch RJ. Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin. Cancer Lett 109:217-222, 1996.
183. Sumi S, Beauchamp RD, Townsend CM Jr., Pour PM, Ishizuka J, Thompson JC. Lovastatin inhibits pancreatic cancer growth regardless of ras mutation. Pancreas 9:657-661, 1994.
184. Muller C, Bockhorn AG, Klusmeier G, Kiehl M, Roeder C, Kalthoff H, Koch OM. Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as wild-type K-ras oncogene but with different effects on protein phosphorylation and induction of apoptosis. Int J Oncol 12:717-723, 1998.
185. Hjertman M, Wejde J, Drieu A, Carlberg M, Griffiths WJ, Sjovall J, Larsson O. Evidence for protein dolichylation. FEBS Lett 416:235-238, 1997.
186. Drieu A, Wang M, Hjertman M, Malec M, Biegen H, Wejde J, Carlberg M, Larsson O. Mevalonate-regulated mechanisms in cell growth control: Role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to ras prenylation and expression of c-myc. Glycobiology 7:625-633, 1997.
187. Perez-Sala D, Mollinedo F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 199:1209-1215, 1994.
188. Jones KD, Couldwell WT, Hinton DR, Su Y, He S, Anker L, Law RE. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem Biophys Res Commun 205:1681-1687, 1994.
189. Stark WW Jr., Blaskovich MA, Johnson BA, Qian Y, Vasudevan A, Pitt B, Hamilton AD, Sebti SM, Davies P. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. Am J Physiol 275:L55-L63, 1998.
190. Rubins JB, Greatens T, Kratzke RA, Tan AT, Polunovsky VA, Bitterman P. Lovastatin induces apoptosis in malignant mesothelioma cells. Am J Respir Crit Care Med 157:1616-1622, 1998.
191. Ghosh PM, Molt GF, Ghosh-Choudhury N, Radnik RA, Stapleton ML, Ghidoni JJ, Kreisberg JI. Lovastatin induces apoptosis by inhibiting mitotic and postmitotic events in cultured mesangial cells. Biochim Biophys Acta 1359:13-24, 1997.
192. Borner MM, Myers CE, Sartor O, Sei Y, Toko T, Trepel JB, Schneider E. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res 55:2122-2128, 1995.
193. Marcelli M, Cunningham GR, Haidacher SJ, Padayatty SJ, Sturgis L, Kagan C, Denner L. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res 58:76-83, 1998.
194. Lee SJ, Ha MJ, Lee J, Nguyen P, Choi YH, Pirnia F, Kang WK, Wang XF, Kim SJ, Trepel JB. Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21 (WAF1/CIP1) in human prostate carcinoma cells. J Biol Chem 273:10618-10623, 1998.
195. McKeon F. Nuclear lamin proteins: Domains required for nuclear targeting, assembly, and cell cycle-regulated dynamics. Curr Opin Cell Biol 3:82-86, 1991.
196. Greenblatt MS, Elias L. The type B receptor for tumor necrosis factor-a mediates DNA fragmentation in HL-60 and U937 cells and differentiation in HL-60 cells. Blood 80:1339-1346, 1992.
197. Hotz MA, Gong J, Traganos F, Darzynkiewicz Z. Flow cytometric detection of apoptosis: Comparison of the assays of in situ DNA degradation and chromatin changes. Cytometry 15:237-244, 1994.
198. Gong J, Traganos F, Darzynkiewicz Z. A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 218:314-319, 1994.
199. Bradfute DL, Simoni RD. Nonsterol compounds that regulate cholesterogenesis: Analogues of farnesyl pyrophosphate reduce 3-hydroxy-3-methylglutaryl-coenzyme A reductase levels. J Biol Chem 269:6645-6650, 1994.
200. Pearce BC, Parker RA, Deason ME, Qureshi AA, Wright JJ. Hypocholesterolemic activity of synthetic and natural tocotrienols. J Med Chem 35:3595-3606, 1992.
201. Pearce BC, Parker RA, Deason ME, Dischino DD, Gillespie E, Qureshi AA, Volk K, Wright JJ. Inhibitors of cholesterol biosynthesis. 2. Hypocholesterolemic and antioxidant activities of benzopyran and tetrahydronaphthalene analogues of the tocotrienols. J Med Chem 37:526-541, 1994.
202. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, Noonan DJ, Burka LT, McMorris T, Lamph WW, Evans RM, Weinberger C. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81:687-693, 1995.
203. Fitch ME, Mangels AR, Altmann WA, El Hawry M, Qureshi AA, Elson CE. Microbiological screening of mevalonate-suppressive minor plant constituents. J Agric Food Chem 37:687-691, 1989.
204. Fuhrman B, Elis A, Aviram M. Hypocholesterolemic effect of lycopene and β-carotene is related to suppression of cholesterol synthesis and augmentation of LDL receptor activity in macrophages. Biochem Biophys Res Commun 233:658-662, 1997.
205. Omkumar RV, Gaikwad AS, Ramasarma T. Feedback-type inhibition of activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ubiquinone. Biochem Biophys Res Commun 184:1280-1287, 1982.
206. Qureshi AA, Pearce BC, Nor RM, Gapor A, Peterson DM, Elson CE. Dietary α-tocopherol attenuates the impact of γ-tocotrienol on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in chickens. J Nutr 126:389-394, 1996.
207. Hayes KC, Pronczuk A, Liang JS. Differences in the plasma transport and tissue concentrations of tocopherols and tocotrienols: Observations in humans and hamsters. Proc Soc Exp Biol Med 202:353-359, 1993.
208. Moreno F, Rossiello MR, Manjeshwar S, Nath R, Rao PM, Rajalakshmi S, Sama DSR. Effect of β-carotene on the expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase in rat liver. Cancer Lett 96:201-208, 1995.
209. Case GL, He L, Mo H, Elson CE. Induction of geranylpyrophosphate pyrophosphatase activity by cholesterol-suppressive isoprenoids. Lipids 30:357-359, 1995.
210. Peffley DM, Mo H, Gayen AK, Elson CE. Functional consequences of the modulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity by isoprenoids. Proc Am Assoc Cancer Res 39:312A, 1998.
211. Elson CE, Underbakke GL, Hanson P, Shrago E, Wainberg R, Qureshi A. Impact of lemongrass oil, an essential oil, on serum cholesterol. Lipids 24:677-679, 1989.
212. Qureshi AA, Bradlow BA, Brace L, Manganello J, Peterson DM, Pearce BC, Wright JJK, Gapor A, Elson CE. Response of hypercholesterolemic subjects to administration of tocotrienols. Lipids 30:1171-1177, 1995.
213. Elson CE, Qureshi AA. Coupling the cholesterol- and tumor-suppressive actions of palm oil to the impact of its minor constituents on 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Prostaglandins Leukot Essent Fatty Acids 52:205-208, 1995.
214. Gruber JR, Ohno S, Niles RM. Increased expression of protein kinase Ca plays a key role retinoic acid-induced melanoma differentiation. J Biol Chem 267:13356-13360, 1992.
215. Kuwashima Y, Matsubara O, Kasuga T. Responses of a murine B16 melanoma to pharmacotherapy studied and compared with different assay systems. J Cancer Res Clin Oncol 116:173-178, 1990.
216. MacNeil S, Wagner M, Buffey J, Hill SE, Finnegan M, Hancock BW, Goyns MH. Signal transduction in murine B16 melanoma cells. Melanoma Res 2:197-206, 1992.
217. Tsukamoto K, Gersten DM, Law LW, Hearing VJ. Malignant melanoma: Relationship to parameters of differentiation. Melanoma Res 1:223-230, 1991.
218. Jani JP, Specht S, Stemmler N, Blanock K, Singh SV, Gupta V, Katoh A. Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. Invasion Metastasis 13:314-324, 1993.
219. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 197:893-895, 1977.
220. Komiyama K, Iizuka K, Yamaoka M, Watanabe H, Tsuchiya N, Umezawa I. Studies on the biological activity of tocotrienols. Chem Pharm Bull 37:1369-1371, 1989.
221. Guthric N, Gapor A, Chambers AF, Carroll KK. Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and -positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination. J Nutr 127:S544-S548, 1997.
222. Russin WA, Hoesly JD, Elson CE, Tanner MA, Gould MN. Inhibition of rat mammary carcinogenesis by monoterpenoids. Carcinogenesis 10:2161-2164, 1989.
223. Zheng G, Kenney PM, Lam LK. Potential anticarcinogenic natural products isolated from lemongrass oil and galanga root oil. J Agric Food Chem 41:153-156, 1983.
224. Ngah WZW, Jarien Z, San MM, Marzuki A, Top GM, Shamaan NA, Kadir KA. Effect of tocotrienols on hepatocarcinogenesis induced by 2-acetylaminofluorence in rats. Am J Clin Nutr 53:S1076-S1081, 1991.
225. Zheng G, Kenney PM, Lam LK. Anethofuran, carvone, and d-limonene: Potential cancer chemopreventive agents from dill weed oil and caraway oil. Planta Med 58:338-341, 1992.
226. Elegbede JA, Elson CE, Qureshi AA, Tanner MA, Gould MN. Inhibition of DMBA-induced mammary cancer by the monoterpene d-limonene. Carcinogenesis 5:661-663, 1984.
227. Elegbede JA, Maltzman TH, Verma AK, Tanner MA, Elson CE, Gould MN. Mouse skin tumor promoting activity of orange peel oil and d-limonene: A reevaluation. Carcinogenesis 7:2047-2049, 1986.
228. Crowell PL, Keenan WS, Haag JD, Ahmad S, Vedejs E, Gould MN. Chemoprevention of mammary carcinogenesis by hydroxylated derivatives of d-limonene. Carcinogenesis 13:1261-1264, 1992.
229. Maltzman TH, Hurt LM, Elson CE, Tanner MA, Gould MN. The prevention of nitrosomethylurea-induced mammary tumors by d-limonene and orange oil. Carcinogenesis 10:781-783, 1989.
230. Goh SH, Hew NF, Norhanom AW, Yadav M. Inhibition of tumor promotion by various palm oil tocotrienols. Int J Cancer 57:529-531, 1994.
231. Shi W, Gould MN. Induction of differentiation in neuro-2A cells by the monoterpene perillyl alcohol. Cancer Lett 95:1-6, 1995.
232. Hohl RJ, Lewis K. Differential effects of monoterpenes and lovastatin on ras processing. J Biol Chem 270:17508-17512, 1995.
233. Marciano D, Ben-Baruch G, Marom M, Egozi Y, Haklai R, Kloog Y. Farnesyl derivatives of rigid carboxylic acids inhibitors of raj-dependent cell growth. J Med Chem 38:1267-1272, 1995.
234. Meigs TE, Sherwood SW, Simoni RD. Farnesyl acetate, a derivative of an isoprenoid of the mevalonate pathway, inhibits DNA replication in hamster and human cells. Exp Cell Res 219:461-470, 1995.
235. Kothapalli R, Guthrie N, Chambers AF, Carroll KK. Farnesylamine: An inhibitor of farnesylation and growth of ras-transformed cells. Lipids 28:969-973, 1993.
236. Tanaka T, Kawabata K, Kakumoto M, Hara A, Murakami A, Kuki W, Takahashi Y, Yonei H, Maeda M, Ota T, Odashima A, Yamane T, Koshimizy K, Ohigashi H. Citrus auraptene exerts dose-dependent chemopreventive activity in rat large bowel tumorigenesis: The inhibition correlates with suppression of cell proliferation and lipid peroxidation and the induction of phase II drug-metabolizing enzymes. Cancer Res 58:2550-2556, 1998.
237. Elson CE, Mo H. Tiglate, anthranilate and benzoate esters of geraniol and farnesol suppress the proliferation of B16 and HL-60 cells. AACR Proceed 40:396, 1999.
238. Jung M, Mo H, Elson CE. Synthesis and biological activity of β-ion-one-derived alcohols for cancer chemoprevention. Anticancer Res 18:189-192, 1998.
239. Schmidt RA, Glomset JA, Wright TN, Habenicht AJR, Ross R. A study of the influence of mevalonic acid and its metabolites on the morphology of Swiss 3T3 cells. J Cell Biol 95:144-153, 1982.
240. Mills JJ, Chari RS, Boyer IJ, Gould MN, Jirtle RL. Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. Cancer Res 55:979-983, 1995.
241. Shimizu T, Cao CX, Shao RG, Pommier Y. Lamin B phosphorylation by protein kinase C and proteolysis during apoptosis in human leukemia HL-60 cells. J Biol Chem 273:8669-8674, 1998.
242. Ariazi EA, Gould MN. Identifying differential gene expression in monoterpene-treated mammary carcinomas using subtractive display. J Biol Chem 271:29286-29294, 1996.
243. Steele VE, Kelloff GJ, Wilkinson BP, Arnold JT. Inhibition of transformation in cultured rat tracheal epithelial cells by potential chemopreventive agents. Cancer Res 50:2068-2074, 1990.
244. Jirtle RL, Haag JD, Ariazi EA, Gould MN. Increased mannose-6-phosphate-insulin-like growth factor II receptor and transforming growth factor β-1 levels during monoterpene-induced regression of mammary tumors. Cancer Res 53:3849-3852, 1993.
245. Williams DH, Stone MJ, Hauck PR, Rahman SK. Why are secondary metabolites (natural products) biosynthesized? J Nat Prod 52:1189-1208, 1989.
246. Scriber JM, Ayres MP. Leaf chemistry as a defense against insects. Anim Plant Sci 1:117-123, 1988.
247. Dahiya JS, Strange RN, Bilyard KG, Cooksey CJ, Garratt PJ. Two isoprenylated isoflavone phytoalexins from Cajanus cajan. Phytochem 23:871-874, 1984.
248. Janssen AM, Scheffer JJ, Baerheim Svendsen A. Antimicrobial activities of essential oils. A 1976-1986 literature review on possible applications. Pharm Weekbl (Sci) 9:193-197, 1987.
249. De Rosa S, De Giulio A, Iodice C. Biological effects of prenylated hydroquinones: Structure-activity relationship studies in antimicrobial, brine shrimp, and fish lethality assays. J Nat Prod 57:1711-1716, 1994.
250. Tahara S, Katagiri Y, Ingham JL, Mizutani J. Prenylated flavonoids in the roots of yellow lupin. Phytochem 36:1261-1271, 1994.
251. Rahalison L, Benathan M, Monod M, Frenk E, Gupta MP, Solis PN, Fuzzati N, Hostettmann K. Antifungal principles of Baccharis pedunculata. Planta Med 61:360-362, 1995.
252. Klepzig KD, Smalley EB, Raffa KF. Combined chemical defenses against an insect-fungal complex. J Chem Ecol 22:1367-1388, 1996.
253. Saito K, Okabe T, Inamori Y, Tsujibo H, Miyake Y, Hiraoka K, Ishida N. The biological properties of monoterpenes: Hypotensive effects on rats and antifungal activities on plant pathogenic fungi of monoterpenes. Mokuzai Gakkaishi 42:677-680, 1996.
254. Pare PW, Tumlinson JH. De novo biosynthesis of volatiles induced by insect herbivory in cotton plants. Plant Physiol 114:1161-1167, 1997.
255. Sadof CS, Grant GG. Monoterpene composition of Pinus sylvestris varieties resistant and susceptible to Dioryctria zimmermani. J Chem Ecol 23:1917-1927, 1997.
256. Snyder JC, Guo Z, Thacker R, Goodman JP, St. Pyrek J. 2,3-Dihydrofarnesoic acid, a unique terpene from trichomes of Lycopersicon hirsutum, repels spider mites. J Chem Ecol 19:2981-2997, 1993.
257. Setzer WN, Green TJ, Lawton RO, Mortality DM, Bates RB, Caldera S, Haber WA. An antibacterial vitamin E derivative from Tovomitopsis psychotriifolia. Planta Med 61:275-276, 1995.
258. Wilson DM, Gueldner RC, McKinney JK, Lievsay RH, Evans BD, Hill RA. Effect of β-ionone on Aspergillus flavus and Aspergillus parasiticus growth, sporulation, morphology and aflatoxin production. JAOCS 58:959A-961A, 1981.
259. Salt SD, Tuzun S, Kuc J. Effects of β-ionone and abscisic acid on the growth of tobacco and resistance to blue mold: Mimicry of effects of stem infection by Peronospora tabacina Adam. Physiol Mol Plant Pathol 28:287-297, 1986.
260. Wei CI, Tan H, Fernando S, Ko NJ. Inhibitory effect of β-ionone on growth and aflatoxin production by Aspergillus parasiticus on peanuts. J Food Protect 49:515-518, 1986.
261. Wall ME, Wani MC. Camptothecin and taxol: From discovery to clinic. J Ethnopharmacol 51:239-254, 1996.
262. Pisha E, Chuai H, Lee IK, Chagwedera TE, Farnsworth NR, Cordell GA, Beecher CWW, Fong HHS, Kinghorn AD, Brown DM, Wani MC, Wall ME, Hieken TJ, Das Gupta TK, Pezzuto JM. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med 1:1046-1051, 1995.
263. Craig WJ. Phytochemicals: Guardians of our health. J Am Diet Assoc 97:S199-S204, 1997.
264. Crowell PL. Monoterpenes in breast cancer chemoprevention. Breast Cancer Res Treat 46:191-197, 1997.
265. Gould MN. Cancer chemoprevention and therapy by monoterpenes. Environ Health Perspect 105(Suppl 4):977-979, 1997.
266. Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet RA, Doody LA, Malone WF, Hawk ET, Sigman CC. New agents for cancer chemoprevention. J Cell Biochem 26:S1-S28, 1996.
267. Greenwald P, Kelloff GJ, Boone CW, McDonald SS. Genetic and cellular changes in colorectal cancer: Proposed targets of chemopreventive agents. Cancer Epidemiol Biomarkers Prev 4:691-702, 1995.
268. Tong ST. Trace components in flavours. Int Flav Food Addit 6:350-355, 1975.
269. Horvat RJ, Senter SD, Dekazos ED. GLC-MS analysis of volatile constituents in rabbiteye blueberries. J Food Sci 48:278-279, 1983.
270. Umeda K, Tanaka Y, Sato S. Citrus carotenoids. VI. The redder carotenoid group contained in the peel of Citrus unshiu var. Benidobashi. J Food Sci Technol 18:482-487, 1971.
271. Sefton MA, Williams PJ. Generation of oxidation artifacts during the hydrolysis of norisoprenoid glycosides by fungal enzyme preparations. J Agric Food Chem 39:1994-1997, 1991.
272. Etievant PX, Issanchou SN, Bayonove CL. The flavor of muscat wine: The sensory contribution of some volatile compounds. J Sci Food Agric 34:497-504, 1983.
273. Krammer G, Winterhalter P, Schwab M, Schreier P. Glycosidically bound aroma compounds in the fruits of Prunus spp.: Apricot (Prunus armeniaca L.), peach (Prunus persica, L.), yellow plum (Prunus domestica ssp. syriaca). J Agric Food Chem 39:778-781, 1991.
274. Larsen M, Poll L, Callensen O, Lewis M. Relations between the content of aroma compounds and the sensory evaluation of 10 raspberry varieties (Rubus idacus L). Acta Agric Scand 41:447-454, 1991.
275. Pabst A, Barron D, Semon E, Schreier P. A 4-hydroxy-β-ionone disaccharide glycoside from raspberry fruits. Phytochem 31:3105-3107, 1992.
276. Shamaila M, Skura B, Daubeny H, Anderson A. Sensory, chemical and gas, chromatographic evaluation of five raspberry cultivars. Food Res Int 26:443-449, 1993.
277. Vereshchagin PV. Essential oils of strawberries and their effect on aroma. Prikl Biokhim Mikrobiol 10:166-169, 1974.
278. Chung TY, Kato HH, Hayase F. Volatile components of ripe tomatoes and their juices, purees and pastes. J Agric Biol Chem 47:343-352, 1983.
279. Buttery RG, Teranishi R, Flath RA, Ling LC. Identification of additional tomato paste volatiles. J Agric Food Chem 38:792-795, 1990.
280. Buttery RG, Teranishi R, Ling LC, Turnbaugh JG. Quantitative and sensory studies on tomato paste volatiles. J Agric Food Chem 38:336-340, 1990.
281. Kato-Noguchi H. Occurrence of a growth inhibitor, 3-hydroxy-β-ionone, in seven cultivars of Phaseolus vulgaris and its role in light-induced growth inhibition. Phytochem 36:273-275, 1994.
282. Hansen M, Buttery RG, Stern DJ, Cantwell MI, Ling LC. Broccoli storage under low-oxygen atmosphere: Identification of higher boiling volatiles. J Agric Food Chem 40:850-852, 1992.
283. Ryan MF, Guerin PM. Behavioral responses of the carrot fly larva, Psila rosae, to carrot root volatiles. Physiol Entomol 7:315-324, 1982.
284. Gueldner RC, Wilson DM, Heidt AR. Volatile compounds inhibiting Aspergillus flavus. J Agric Food Chem 33:411-413, 1985.
285. Purcell AE, Later DW, Lee ML. Analysis of the volatile constituents of baked, Jewel sweet potatoes. J Agric Food Chem 28:939-941, 1980.
286. Etoh H, Ina K, Iguchi M. 3S-(+)-3,7-dimethyl-1,5-octadiene-3,7-diol and ionone derivatives from tea. Agric Biochem 44:2999-3000, 1990.
287. Kubo I, Morimitsu Y. Cytotoxicity of green tea flavor compounds against two solid tumor cells. J Agric Food Chem 43:1626-1628, 1995.
288. Jung HP, Sen A, Grosch W. Evaluation of potent odorants in parsley leaves (Petroselinum crispum ssp. crispum) by aroma extract dilution analysis. Leb Wissen Technol 25:55-60, 1992.
289. Peterson DM, Qureshi AA. Genotype and environment effects on tocols of barley and oats. Cereal Chem 70:157-162, 1993.
290. Rogers EJ, Rice SM, Nicolosi RJ, Carpenter DR, McClelland CA, Romanczyk LJ Jr. Identification and quantitation of γ-oryzanol components and simultaneous assessment of tocols in rice bran oil. JAOCS 70:301-307, 1993.
291. Slover HT, Lehmann J, Valis RJ. Nutrient composition of selected wheats and wheat products. III. Tocopherols. Cereal Chem 46:635-641, 1969.
292. Hassapidou MN, Balatsouras GD, Manoukas AG. Tocopherol and tocotrienol compositions of raw table olive fruit. J Sci Food Agric 61:277-280, 1993.
293. Hassapidou MN, Balatsouras GD, Manoukas AG. Effect of processing upon the tocopherol and tocotrienol composition of table olives. Food Chem 50:111-114, 1994.
294. Hernandez-Rabascall N, Boatella-Riera J. Variations in the tocopherol and tocotrienol content during refining and hydrogenation of edible oils. Grasas Aceites 38:145-148, 1987.
295. Micali G, Curro P. Determination of tocopherols in vegetable oils by HPLC. Rivista Ital Sostanze Grasse 61:95-98, 1984.
296. Goh SH, Choo YM, Ong ASH. Minor constituents of palm oil. JAOCS 62:237-240, 1985.
297. Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: A review of the epidemiological evidence. Nutr Cancer 18:1-29, 1992.
298. Steinmetz KA, Potter JD. Vegetables, fruit, and cancer. II. Mechanisms. Cancer Causes Control 2:427-442, 1991.
299. Willet WC. Diet and health: What should we eat? Science 64:532-537, 1994.
300. DeCosse JJ, Miller HH, Lesser ML. Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polypsis. J Natl Cancer Inst 81:1290-1297, 1989.
301. MacLennan R, Macrac F, Bain C, Battistutta D, Chapius P, Gratten H, Lambert J, Newland RC, Ngu M, Russell A, Ward M, Wahlqvist ML. Randomized trial of intake of fat, fiber, and β-carotene to prevent colorectal adenomas: The Australian Polyp Prevention Project. J Natl Cancer Inst 87:1760-1766, 1995.
302. McKeown-Eyssen GE, Bright-See E, Bruce WR, Jazmaji VA. A randomized trial of a low-fat, high-fibre diet in the recurrence of colorectal polyps: Toronto Polyp Prevention Group. J Clin Epidemiol 47:525-536, 1994.
303. Greenberg ER, Baron JA, Tosteson TD, Freeman DH Jr, Beck GJ, Bond JH, Colacchio TA, Coller JA, Frankl HD, Haile RW, Mandel JS, Nierenberg DW, Rothstein R, Snover DC, Stevens MM, Summers RW, van Stolk RU. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. N Engl J Med 331:141-147, 1994.
304. Losonoczy KG, Harris TB, Havlik RJ. Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: The established populations for epidemiologic studies of the elderly. Am J Clin Nutr 64:190-196, 1996.
305. Hunter DJ, Manson JE, Colditz GA, Stampfer MJ, Rosner B, Hennekens CH, Speizer FE, Willett WC. A prospective study of the intake of vitamins C, E, and A and the risk of breast cancer. N Engl J Med 329:234-240, 1993.
306. Albanes D, Heinonen OP, Taylor PR, Virtamo J, Edwards BK, Rautalahti M, Hartman AM, Palmgren J, Freedman LS, Haapakoski J, Barrett MJ, Pietinen P, Malila N, Tala E, Liippo K, Salomaa ER, Tangrea JA, Teppo L, Askin FB, Taskinen E, Erozan Y, Greenwald P, Huttunen JK. (1996). α-Tocopherol and β-carotene supplements and lung cancer incidence in the α-tocopherol, β-carotene cancer prevention study: Effects of baseline characteristics and study compliance. J Natl Cancer Inst 88:1560-1570, 1996.
307. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar S. Effects of a combination of β-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150-1155, 1996.
308. The α-Tocopherol, β-Carotene Cancer Prevention Study Group. The effect of vitamin E and β-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330:1029-1035, 1994.
309. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto R. Lack of effect of long-term supplementation with β-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334:1145-1149, 1996.
310. Hunter DJ, Colditz GA, Stampfer MJ, Rosner B, Willelt WC, Speizer FE. Diet and risk of basal cell carcinoma of the skin in a prospective cohort of women. Ann Epidemiol 2:231-239, 1992.
311. Kushi LH, Fee RM, Sellers TA, Zheng W, Folsom AR. Intake of vitamins A, C, and E and postmenopausal breast cancer: The Iowa Women's Health Study. Am J Epidemiol 144:165-174, 1996.
312. Byers T, Guerrero N. Epidemiologic evidence for vitamin C and vitamin E in cancer prevention. Am J Clin Nutr 62:S1385-S1392, 1995.
313. Giovannucci E, Stampfer MJ, Colditz GA, Hunter DJ, Fuchs C, Rosner BA, Speizer FE, Willen WC. Multivitamin use, folatc, and colon cancer in women in the Nurses' Health Study. Ann Intern Med 129:5217-5224, 1998.
314. Baron JA, Sandler RS, Haile RW, Mandel JS, Mott LA, Greenberg ER. Folate intake, alcohol consumption, cigarette smoking, and risk of colorectal adenomas. J Natl Cancer Inst 90:57-62, 1998.
315. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 87:1767-1776, 1995.